<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Diagnosis of invasive aspergillosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Diagnosis of invasive aspergillosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Diagnosis of invasive aspergillosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Thomas F Patterson, MD, FACP, FIDSA</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carol A Kauffman, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Keri K Hall, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 05, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H30927008"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The term "aspergillosis" refers to illness due to allergy, airway or lung invasion, cutaneous infection, or extrapulmonary dissemination caused by species complexes of <em>Aspergillus</em>, most commonly <em>A. fumigatus</em>, <em>A. flavus</em>, <em>A. niger,</em> and <em>A. terreus</em>. <em>Aspergillus </em>species are ubiquitous in nature, and inhalation of infectious conidia is a common event. However, tissue invasion is uncommon and occurs most frequently in the setting of immunosuppression associated with receipt of therapy for hematologic malignancies or hematopoietic cell or solid organ transplantation.</p><p>The diagnosis of invasive aspergillosis will be reviewed here. The epidemiology, clinical manifestations, and treatment of invasive aspergillosis, as well as the diagnosis of other syndromes caused by <em>Aspergillus</em> spp, are presented elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2454.html" rel="external">"Epidemiology and clinical manifestations of invasive aspergillosis"</a> and  <a class="medical medical_review" href="/z/d/html/2459.html" rel="external">"Treatment and prevention of invasive aspergillosis"</a> and  <a class="medical medical_review" href="/z/d/html/2419.html" rel="external">"Clinical manifestations and diagnosis of allergic bronchopulmonary aspergillosis"</a> and  <a class="medical medical_review" href="/z/d/html/2441.html" rel="external">"Chronic pulmonary aspergillosis: Epidemiology, clinical manifestations and diagnosis"</a>.)</p><p class="headingAnchor" id="H977449123"><span class="h1">APPROACH TO DIAGNOSIS</span></p><p class="headingAnchor" id="H2411495071"><span class="h2">General approach</span><span class="headingEndMark"> — </span>Culture of <em>Aspergillus</em> spp in combination with the histopathologic demonstration of tissue invasion by hyphae provides definitive evidence of invasive aspergillosis [<a href="#rid1">1,2</a>]. However, biopsy is frequently not feasible due to the risks of complications (eg, bleeding risk in patients with thrombocytopenia). </p><p>A rational first step to establishing the diagnosis of invasive aspergillosis involves the use of less invasive modalities, such as serum biomarkers (galactomannan, beta-D-glucan, and polymerase chain reaction [PCR] assays), and obtaining sputum and/or bronchoalveolar lavage (BAL) specimens for fungal staining, fungal culture, BAL galactomannan, and/or PCR. </p><p>A positive sputum fungal stain and/or culture should prompt therapy of hosts who are at risk for invasive aspergillosis. In the right clinical context, a positive BAL galactomannan antigen, BAL PCR for aspergillus species, or a positive serum galactomannan antigen can also provide a presumptive diagnosis [<a href="#rid2">2-4</a>]. In contrast, a positive serum beta-D-glucan assay can occur in the setting of various invasive fungal infections, including candidiasis. </p><p>Patients with clinical and radiographic findings that are suggestive of an invasive fungal infection, but in whom noninvasive testing and/or bronchoscopy is unrevealing, should ideally undergo lung biopsy. </p><p>Options for biopsy include bronchoscopy with transbronchial biopsy, computed tomography-guided transthoracic needle biopsy, and video-assisted thorascopic surgery. The most appropriate technique depends upon the location of the lesion(s), the individual patient's risk of complications from each procedure, and the necessity to establish the diagnosis. The decision regarding the need for a histopathologic diagnosis must be made on a patient-by-patient basis.</p><p class="headingAnchor" id="H718172057"><span class="h2">Approach in patients with COVID-19</span><span class="headingEndMark"> — </span>An increased incidence of pulmonary aspergillosis has been reported in patients with coronavirus disease 2019 (COVID-19) infection, most frequently in patients with severe COVID-19 who are mechanically ventilated, are &gt;65 years of age, have underlying lung disease, and/or have immunocompromising conditions [<a href="#rid5">5,6</a>]. (See  <a class="medical medical_review" href="/z/d/html/2454.html" rel="external">"Epidemiology and clinical manifestations of invasive aspergillosis"</a>.)</p><p>The diagnosis of pulmonary aspergillosis in patients with COVID-19 is challenging because they may lack the classic risk factors for invasive aspergillosis (ie, hematologic malignancies, neutropenia) and radiographic findings [<a href="#rid7">7-9</a>]. </p><p>Suspicion for invasive aspergillosis should be raised in any patient with COVID-19 who has radiographic findings that suggest aspergillosis (ie, nodular opacities with surrounding ground glass infiltrates or cavitary disease). Because typical radiographic findings may be absent or obscured by those due to COVID-19, suspicion should also be raised in any patient with COVID-19 who has prolonged or relapsing respiratory failure without alternate explanation. </p><p>When invasive aspergillosis is suspected, we typically perform a bronchoscopy to directly visualize the airways and perform BAL to obtain samples for microbiologic diagnosis. In general, we perform fungal staining, fungal culture, galactomannan antigen, and/or PCR for <em>Aspergillus</em> on the BAL fluid. While the diagnostic utility of serum biomarkers is less clear in patients with COVID-19, we usually obtain both a serum galactomannan test and a beta-D-glucan test because positive results can help corroborate the diagnosis of invasive aspergillosis. Serum PCR testing should be performed, if available. These tests are typically performed as part of a more comprehensive evaluation for respiratory failure. A blind nonbronchoscopic lavage can be obtained if bronchoscopy is not feasible due to infection control concerns or other factors [<a href="#rid9">9</a>]. Tracheal aspirates can be used in conjunction with other assessments, but positive culture results and/or galactomannan results may reflect colonization rather than invasive disease [<a href="#rid7">7,9</a>]. (See  <a class="medical medical_review" href="/z/d/html/1635.html" rel="external">"Clinical presentation and diagnostic evaluation of ventilator-associated pneumonia", section on 'Invasive respiratory sampling'</a>.)</p><p>For patients who have radiographic findings consistent with aspergillosis (ie, nodules or cavities) and lack of concern for other causes, detection of aspergillosis by culture, BAL or serum galactomannan, and/or PCR is typically sufficient for diagnosis. When consistent radiographic findings are absent, it is difficult to determine whether the detection of <em>Aspergillus</em> in the airways represents colonization or active infection; in such cases, we typically make the decision to treat on a case-by-case basis. </p><p>Our approach is similar to that outlined by an expert task force on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis [<a href="#rid8">8,9</a>]. </p><p>Treatment is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2459.html" rel="external">"Treatment and prevention of invasive aspergillosis"</a>.)</p><p class="headingAnchor" id="H1064486416"><span class="h1">DIAGNOSTIC MODALITIES</span><span class="headingEndMark"> — </span><em>Aspergillus</em> species are frequently inhaled into the airways, but because of effective conidial clearance in the majority of individuals, disease usually does not result. Because we inhale conidia constantly, culture isolation of <em>Aspergillus</em> species from the airway does not necessarily indicate disease. Thus, the diagnosis of invasive aspergillosis is based upon both isolating the organism (or markers of the organism) and the probability that it is the cause of disease. The latter is a function of the host's risk factors for disease (eg, immune status) and the clinical presentation. Demonstration of hyphal elements invading tissues from biopsy of any affected site, such as the lung or skin, represents a proven diagnosis [<a href="#rid10">10</a>].</p><p>Given the above issues, the diagnosis of invasive aspergillosis is often referred to within a scale of certainty: possible, probable, or proven [<a href="#rid2">2,10,11</a>]. These definitions have been developed in order to maintain consistency in clinical and epidemiologic studies, not to drive therapeutic decision making.</p><p class="headingAnchor" id="H58499699"><span class="h2">Direct examination of respiratory specimens</span><span class="headingEndMark"> — </span>Respiratory specimens are usually stained with calcofluor white with 10% potassium hydroxide to detect the presence of fungal elements [<a href="#rid12">12</a>]. Gomori methenamine silver can be used to stain cytology preparations. Organisms can be observed as narrow (3 to 6 microns wide), septated hyaline hyphae with dichotomous acute angle (45°) branching [<a href="#rid13">13</a>]. However, several filamentous fungi, including <em>Scedosporium</em> spp and <em>Fusarium</em> spp, have similar appearances to <em>Aspergillus</em> spp on direct microscopy.</p><p class="headingAnchor" id="H1064486423"><span class="h2">Culture</span><span class="headingEndMark"> — </span>Culture of the organism, in combination with evidence of tissue invasion on histopathology or culture from a normally sterile site, provides the most certain evidence of invasive aspergillosis [<a href="#rid10">10</a>]. However, both microscopic examination and culture are insensitive [<a href="#rid14">14</a>], and therapy should not be withheld in the absence of such confirmation. Furthermore, performing a biopsy is not feasible in some patients due to bleeding risk or risk of other complications. In patients with risk factors and clinical and/or radiographic features that are suggestive of invasive aspergillosis, culture of <em>Aspergillus</em> spp from respiratory secretions provides adequate evidence of invasive disease.</p><p><em>Aspergillus</em> is a rapidly growing fungus in the laboratory and is often visible in culture within one to three days of incubation. Sporulation is required for examination of spore-bearing structures, and diagnosis at the species complex level. Molecular testing is required for definitive diagnosis of the specific species within the complex. </p><p>Occasionally, organisms can be difficult to identify due to slow sporulation. Slow sporulating organisms may have been disregarded as non-pathogens in the past. However, more recently, slow-sporulating species (eg, <em>Aspergillus lentulus</em>, <em>Neosartorya udagawae</em>,<em> </em>and others) with variable susceptibility profiles have been identified and implicated in invasive infections [<a href="#rid15">15</a>]. These organisms should not be disregarded as contaminants based on the slow-sporulating phenotype. (See  <a class="medical medical_review" href="/z/d/html/2459.html" rel="external">"Treatment and prevention of invasive aspergillosis", section on 'Consideration of antifungal resistance'</a>.)</p><p>Many patients with documented invasive aspergillosis have negative cultures. This has been observed in surveillance studies, and the prevalence of negative cultures varies depending upon the population being evaluated. As an example, in multicenter surveillance studies, only 25 to 50 percent of hematopoietic cell transplant (HCT) recipients who met criteria for invasive aspergillosis based upon galactomannan antigen results had positive cultures [<a href="#rid16">16,17</a>].</p><p>The predictive value of positive sputum or bronchoalveolar lavage (BAL) cultures is dependent upon both the host and the clinical presentation. In a study that evaluated the predictive value of lower respiratory tract cultures in different patient populations with probable or proven invasive pulmonary aspergillosis, the positive predictive value was highest in HCT recipients, patients with hematological malignancies, and granulocytopenic patients (72 percent), compared with solid organ transplant recipients and patients receiving glucocorticoids (58 percent) and patients with HIV (14 percent) [<a href="#rid18">18</a>]. The positive predictive value was highest in BAL cultures, in part because the prevalence of invasive aspergillosis is higher among patients who have radiographic abnormalities warranting bronchoscopy. Clinical and radiographic findings suggestive of invasive aspergillosis were present significantly more often among infected patients compared with uninfected patients.</p><p class="headingAnchor" id="H14377219"><span class="h2">Histopathology</span><span class="headingEndMark"> — </span>In the setting of invasive disease, organisms can be observed in biopsy specimens as narrow (3 to 6 microns wide), septated hyaline hyphae with dichotomous acute angle (45°) branching  (<a class="graphic graphic_picture graphicRef68747" href="/z/d/graphic/68747.html" rel="external">picture 1</a> and <a class="graphic graphic_picture graphicRef57220" href="/z/d/graphic/57220.html" rel="external">picture 2</a> and <a class="graphic graphic_picture graphicRef70889" href="/z/d/graphic/70889.html" rel="external">picture 3</a>). The organism can be seen using Gomori methenamine silver or periodic acid-Schiff staining. However, several hyaline molds, including <em>Scedosporium</em> spp and <em>Fusarium</em> spp, have similar appearances to <em>Aspergillus</em> spp in histopathologic sections. Since the treatment of infections caused by these fungi may differ, it is important to confirm genus and species by culture. (See  <a class="medical medical_review" href="/z/d/html/16218.html" rel="external">"Clinical manifestations and diagnosis of Fusarium infection", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/z/d/html/2424.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of Scedosporium and Lomentospora infections", section on 'Histopathology'</a>.)</p><p>Histopathologic examination can sometimes distinguish the above organisms from the order Mucorales(the agents of mucormycosis), which appear as broad, nonseptate hyphae that exhibit right-angle branching  (<a class="graphic graphic_picture graphicRef66476" href="/z/d/graphic/66476.html" rel="external">picture 4</a> and <a class="graphic graphic_picture graphicRef72487" href="/z/d/graphic/72487.html" rel="external">picture 5</a>). Occasionally, this distinction can be difficult, especially when small hyphal fragments are present or when the organism folds back on itself to create "pseudo-septations." Determining whether the fungus is one of the Mucorales or another fungus is important because the Mucorales are not susceptible to <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a>, which is the treatment of choice for invasive aspergillosis. (See  <a class="medical medical_review" href="/z/d/html/2465.html" rel="external">"Mucormycosis (zygomycosis)"</a> and  <a class="medical medical_review" href="/z/d/html/2459.html" rel="external">"Treatment and prevention of invasive aspergillosis"</a>.)</p><p class="headingAnchor" id="H1064486430"><span class="h2">Galactomannan antigen detection</span><span class="headingEndMark"> — </span>Galactomannan is a polysaccharide that is a major constituent of <em>Aspergillus</em> cell walls. A double sandwich enzyme immunoassay (EIA) that utilizes the monoclonal antibody EB-A2 forms the current commercial (Platelia) assay, which has been approved by the US Food and Drug Administration (FDA) for testing serum and BAL fluid. This antibody detects multiple epitopes on galactofuranose side chains that are linked to the large polymer mannan backbone [<a href="#rid19">19</a>]. Galactofuranose is the six-member ring form of galactose, which is made by non-mammalian eukaryotes and some prokaryotic pathogens, and is a common antigenic moiety of different glycoconjugates [<a href="#rid20">20</a>]. Although once described as being <em>Aspergillus </em>specific, we now know that galactofuranose is present in other fungi and certain other substances. (See <a class="local">'Caveats'</a> below.)</p><p class="headingAnchor" id="H22230119"><span class="h3">Interpretation</span><span class="headingEndMark"> — </span>The galactomannan EIA is performed with an optical read-out that is interpreted as a ratio relative to the optical density (OD) of a threshold control provided by the manufacturer; this ratio is called the OD index. Initial use of the test, largely in Europe, utilized a relatively high OD index (1 to 1.5) as a cut-off for positivity in order to ensure few false-positive results. Subsequent studies demonstrated that lower thresholds (0.5 to 0.7) provide relatively better performance [<a href="#rid21">21,22</a>]. The assay cleared by the FDA has a suggested threshold OD index of 0.5; thus, an OD index ≥0.5 is considered to be a positive result. For clinical trial purposes, in order to ensure a higher likelihood of diagnostic certainty, a threshold OD index of ≥1.0 in serum or plasma has been proposed and included in the European Organisation for Research and Treatment of Cancer (EORTC)/Mycoses Study Group Education and Research Consortium (MSGERC) definitions [<a href="#rid2">2,23</a>].</p><p class="headingAnchor" id="H1064486437"><span class="h3">Serum</span><span class="headingEndMark"> — </span>In some patients, galactomannan antigen can be detected in the serum before the presence of clinical signs or symptoms of invasive aspergillosis. Several studies have assessed its test characteristics, and the performance of the test has been addressed in a review and meta-analysis [<a href="#rid24">24,25</a>]. Some inconsistency in the reported performance of the test has been introduced by studies that used different cut-offs for positivity as well as other variables, such as different populations evaluated and testing on patients receiving concurrent antifungal drugs. One review noted that the sensitivity of the test varied from 30 to 100 percent, whereas specificity remained relatively high and constant (&gt;75 percent) [<a href="#rid26">26</a>].</p><p>A meta-analysis that included 50 studies with a total of 5660 immunocompromised patients, including 586 with proven or probable invasive aspergillosis, reported that using an OD index cutoff of 0.5, sensitivity of the galactomannan EIA was 82 percent (95% CI 73-90 percent) and specificity was 81 percent (95% CI 72-90 percent) [<a href="#rid25">25</a>].</p><p>In another meta-analysis, subgroup analyses suggested that the assay performs better in patients who have a hematologic malignancy or who have received HCT; in comparison, the test performance may be limited in solid organ transplant recipients [<a href="#rid27">27</a>]. Whether this is related to biologic differences in the type of invasive disease, such as degree of fungal burden, is unclear. Few cases were included in the studies that have been performed; more patients who have different underlying diseases will need to be studied to establish the usefulness of this assay in disparate populations.</p><p class="headingAnchor" id="H1064486444"><span class="h4">Caveats</span><span class="headingEndMark"> — </span>The following caveats should be considered when using the galactomannan EIA:</p><p class="bulletIndent1"><span class="glyph">●</span>The sensitivity of detecting galactomannan in serum is decreased by concurrent administration of mold-active antifungal therapy [<a href="#rid28">28-30</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the past, false-positive serum results were demonstrated in patients who were receiving intravenous <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a> due to the presence of galactomannan (or a cross-reactive antigen) in the antibiotic formulation [<a href="#rid31">31,32</a>]. False-positive results persisted for as long as five days after discontinuation of piperacillin-tazobactam [<a href="#rid32">32,33</a>]. Results of more recent studies suggest that current preparations of piperacillin-tazobactam rarely react with the assay [<a href="#rid34">34,35</a>]. False-positive galactomannan results have also been reported with intravenous <a class="drug drug_general" data-topicid="8676" href="/z/d/drug information/8676.html" rel="external">amoxicillin-clavulanate</a>, a formulation that is not available in the United States [<a href="#rid36">36</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Many fungi demonstrate galactomannans (or polysaccharides containing galactofuranose residues) on their cell walls. False-positive results of the <em>Aspergillus</em> galactomannan EIA may be seen with infections caused by organisms that share cross-reacting antigens. These include filamentous Ascomycetes that cause similar disease presentations (eg, <em>Fusarium</em> species [<a href="#rid37">37</a>]) and others (<em>Penicillium </em>species<em> </em>[<a href="#rid38">38</a>], <em>Histoplasma capsulatum</em> [<a href="#rid39">39</a>]).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>False-positive results are more likely to occur during the first 100 days following HCT and in patients with gastrointestinal tract mucositis caused by chemotherapy or graft-versus-host disease (GVHD) [<a href="#rid40">40</a>]. The proposed mechanism is that galactomannan in foods or bacteria having cross-reactive epitopes may translocate across the intestinal mucosa during periods of impaired mucosal integrity [<a href="#rid31">31</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another possible cause of false-positive galactomannan EIA results is contamination of foods with <em>Aspergillus</em> or closely related fungi, such as <em>Penicillium</em> spp. One report noted false-positive results associated with ingestion of large numbers of frozen ice-pops in the setting of gastrointestinal GVHD [<a href="#rid41">41</a>]. Possible causes included <em>Penicillium</em> contamination of the ice-pop wrappers or a food additive in the ice pops, such as sodium gluconate.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>False-positive results have been reported in patients who received transfusions of blood products that were collected in bags produced by a single manufacturer (Fresenius Kabi, Germany) but not in patients who received blood products that were collected in bags produced by other manufacturers [<a href="#rid42">42</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In one study, some patients who received intravenous immunoglobulin had a false-positive galactomannan EIA result [<a href="#rid43">43</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Some false-positive results have been reported in children, in whom the assay has been less well studied. However, other studies suggest relatively little false positivity, with similar results to those in adults [<a href="#rid44">44</a>].</p><p></p><p class="headingAnchor" id="H613737206"><span class="h4">Role of testing</span><span class="headingEndMark"> — </span>Studies evaluating the serum galactomannan EIA report relatively low (&lt;50 percent) and high (&gt;90 percent) positive and negative predictive values, respectively. These values are largely a function of the low prevalence of disease, even when measured in high-risk populations (usually &lt;20 percent). One should thus consider the clinical context to determine the probability of infection [<a href="#rid26">26</a>]. (See  <a class="medical medical_review" href="/z/d/html/2759.html" rel="external">"Glossary of common biostatistical and epidemiological terms", section on 'Predictive values'</a>.)</p><p>Some investigators have suggested using the serum galactomannan EIA for screening (weekly or twice weekly) in order to detect invasive aspergillosis prior to the development of clinical signs or symptoms. Biomarker screening as a means to guide pre-emptive therapy was evaluated in a randomized trial; screening with galactomannan antigen and PCR led to reduced empiric antifungal treatment compared with a culture-based strategy [<a href="#rid45">45</a>]. The use of biomarker-driven strategies allows less empiric use of antifungal therapy for fever and more pre-emptive therapy based on positive biomarker results [<a href="#rid1">1,2</a>]. (See  <a class="medical medical_review" href="/z/d/html/2459.html" rel="external">"Treatment and prevention of invasive aspergillosis", section on 'Pre-emptive therapy'</a>.)</p><p>The utility of the serum galactomannan EIA has been best established in the setting of suspected disease in high-risk patients with hematologic malignancies. In the setting of clinical disease suspicion, prevalence is higher, assuring better predictive performance. The assay may also be useful in other immunocompromised patients at risk for invasive pulmonary aspergillosis, but caution is necessary in interpreting results as sensitivity is not as high in patients who have disease that may be limited to the airways (eg, lung transplant recipients). (See  <a class="medical medical_review" href="/z/d/html/1394.html" rel="external">"Fungal infections following lung transplantation", section on 'Galactomannan, beta-D-glucan, and PCR'</a>.)</p><p>Some investigators have suggested a role for serial galactomannan testing in patients with documented invasive aspergillosis, both as a prognostic measure of effectiveness of antifungal therapy and to differentiate between worsening fungal infection and worsening radiographic findings developing as a result of the host immune response [<a href="#rid46">46-50</a>]. The prognostic value of the serum galactomannan EIA is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2459.html" rel="external">"Treatment and prevention of invasive aspergillosis", section on 'Prognostic factors'</a>.)</p><p class="headingAnchor" id="H169260052"><span class="h3">Bronchoalveolar lavage fluid</span><span class="headingEndMark"> — </span>The galactomannan EIA detects fungal antigens even when the organism does not grow in the laboratory, providing an indication of potentially invasive disease. The galactomannan EIA performed on BAL fluid provides additional sensitivity compared with culture, estimated in most studies to exceed 70 percent [<a href="#rid51">51-55</a>].</p><p>The optimal threshold OD index for positivity continues to be debated; a higher threshold OD index results in lower sensitivity but higher specificity for invasive aspergillosis. In a meta-analysis of studies of BAL galactomannan in immunocompromised patients, an OD cutoff of 0.5 resulted in a sensitivity of 0.88 and a specificity of 0.81, whereas a cutoff of 1.0 resulted in a sensitivity of 0.78 and a specificity of 0.93 [<a href="#rid55">55</a>]. As noted above, the FDA considers an OD index of ≥0.5 to be positive for galactomannan EIA in both serum and BAL fluid, although a revised threshold of 1.0 for BAL fluid is now included in the EORTC/MSGERC definitions [<a href="#rid2">2,23</a>]. Higher OD levels are associated with greater diagnostic certainty.</p><p>It is important to note that false-positive results occur, and these are especially common in the setting in which the detection of fungi in the airways represents colonization as occurs in lung transplant recipients or when the fluid that is used for BAL washes is contaminated with galactomannan. However, one study performed in lung transplant recipients suggested that specificity is high (95 percent) [<a href="#rid51">51</a>]. Many centers have begun to utilize this assay on BAL fluid as an adjunct to other diagnostic tests when invasive aspergillosis is suspected. Because performance may be dependent on technical variables, such as type and amount of BAL fluid, institutions should establish specific protocols for testing.</p><p>The use of the galactomannan assay on BAL fluid from lung transplant recipients is discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/1394.html" rel="external">"Fungal infections following lung transplantation", section on 'Galactomannan, beta-D-glucan, and PCR'</a>.)</p><p class="headingAnchor" id="H1064486458"><span class="h3">Other specimen types</span><span class="headingEndMark"> — </span>Although the galactomannan assay has been approved by the FDA for use only on serum and bronchoalveolar lavage fluid, galactomannan can also be detected in other samples, including cerebrospinal fluid and pleural fluid, depending on the clinical context [<a href="#rid56">56</a>].</p><p class="headingAnchor" id="H1064486465"><span class="h2">Beta-D-glucan assay</span><span class="headingEndMark"> — </span>1,3-Beta-D-glucan, a cell wall component of many fungi, is detected by the beta-D-glucan assay. There are several different commercial assays available in different countries. The Fungitell assay has been cleared by the FDA as an aid to diagnose invasive fungal infections. These assays utilize the same principle as serum endotoxin assays, measuring activation of Factor G. Since the different marketed tests utilize different horseshoe crab substrates and different methods to measure output, performance may be variable. The output of the serum assay currently available in the United States is based on spectrophotometer readings, in which optical density is converted to beta-D-glucan concentrations; the results are interpreted as negative (range &lt;60 pg/mL), indeterminate (60 to 79 pg/mL), or positive (&gt;80 pg/mL) [<a href="#rid57">57</a>]. Importantly, these cut-offs were defined in the clinical context of identifying breakthrough invasive fungal infections (primarily, invasive candidiasis) in people who were undergoing treatment for hematologic malignancies. Precise cut-offs to optimize performance of the assay as an aid to diagnose invasive aspergillosis have not been defined and may be different. In a 2011 meta-analysis that included 16 studies evaluating beta-D-glucan assays for the diagnosis of invasive fungal infections, the pooled sensitivity was 77 percent (95% CI 67-84 percent) and the pooled specificity was 85 percent (95% CI 80-90 percent) [<a href="#rid58">58</a>]. A 2012 meta-analysis that included six cohort studies of patients with hematologic malignancies noted a lower sensitivity (50 percent, 95% CI 34-65 percent) and a higher specificity (99 percent, 95% CI 97-100 percent) than previously reported; however, there were few cases of invasive aspergillosis tested to provide definitive conclusions [<a href="#rid59">59</a>]. In individual studies, the sensitivity has ranged from 55 to 95 percent and the specificity has ranged from 77 to 96 percent [<a href="#rid57">57,60-64</a>]. As in studies evaluating other fungal diagnostics, likely reasons for the differences in sensitivity and specificity between studies are that different thresholds were considered positive, different assays were used, patient populations varied, and study design was not uniform. Despite the substantial heterogeneity among different studies, the beta-D-glucan assay has good accuracy for distinguishing patients with proven or probable invasive fungal infections from patients without invasive fungal infection [<a href="#rid58">58</a>].</p><p>One study compared performance of the galactomannan EIA with the beta-D-glucan assay in sera from 105 patients with invasive aspergillosis and 50 healthy blood donors [<a href="#rid65">65</a>]. Results demonstrated a higher specificity with the galactomannan test (97 versus 82 percent) but a lower sensitivity (81 versus 49 percent).</p><p class="headingAnchor" id="H1064486472"><span class="h3">Caveats</span><span class="headingEndMark"> — </span>The following caveats should be considered when using the beta-D-glucan assay:</p><p class="bulletIndent1"><span class="glyph">●</span>The beta-D-glucan assay is not specific for <em>Aspergillus</em> species and can be positive in patients with a variety of invasive fungal infections, including candidiasis and <em>Pneumocystis jirovecii</em> (formerly <em>P. carinii</em>); the latter can be associated with beta-D-glucan levels greater than the upper limits of the assay. Although the beta-D-glucan assay may be positive in patients with a variety of invasive fungal infections, it is typically negative in patients with mucormycosis or cryptococcosis [<a href="#rid62">62,63,66,67</a>]. (See  <a class="medical medical_review" href="/z/d/html/1406.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in patients without HIV", section on 'Beta-D-glucan assay'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The specificity of the assay can be decreased by multiple other clinical variables; the following factors have been reported to cause false-positive results [<a href="#rid66">66</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hemodialysis with cellulose membranes</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Intravenous immunoglobulin</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Albumin</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Use of cellulose filters for intravenous administration</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Gauze packing of serosal surfaces [<a href="#rid68">68</a>]</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Intravenous amoxicillin-clavulanic acid (a formulation that is not available in the United States) [<a href="#rid69">69</a>]</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Infections with certain bacteria that contain cellular beta-glucans, such as <em>Pseudomonas aeruginosa</em> [<a href="#rid70">70,71</a>]</p><p></p><p class="headingAnchor" id="H14378086"><span class="h3">Role of testing</span><span class="headingEndMark"> — </span>The beta-D-glucan assay may be used for detecting invasive fungal infections early in the course of infection, prior to the onset of overt clinical findings. One study evaluated a screening strategy in which 95 patients receiving chemotherapy for acute leukemia underwent beta-D-glucan testing twice weekly in the absence of fever and daily in the presence of fever [<a href="#rid72">72</a>]. Screening appeared to shorten the time interval between suspected infection and established diagnosis, when compared with waiting for clinical signs and symptoms of disease. However, this strategy has not been validated in randomized trials. Because of its limited sensitivity, beta-D-glucan testing should not be used to rule out invasive fungal infections, particularly in patients with hematologic malignancies due to the high prevalence of invasive fungal infections in this population [<a href="#rid73">73</a>]. (See  <a class="medical medical_review" href="/z/d/html/2459.html" rel="external">"Treatment and prevention of invasive aspergillosis", section on 'Pre-emptive therapy'</a>.)</p><p class="headingAnchor" id="H1064486480"><span class="h2">Polymerase chain reaction</span><span class="headingEndMark"> — </span>When invasive aspergillosis is suspected, we typically include PCR, in conjunction with other biomarkers, in our diagnostic evaluation. PCR can be performed on serum, plasma, whole blood, or BAL fluid. As with other biomarkers, diagnostic certainty rises with two consecutive positive results. In addition to diagnosis, some PCR-based assay can detect mutations associated with antifungal resistance [<a href="#rid3">3</a>]. </p><p>Molecular assays (eg, by PCR) have undergone extensive evaluation [<a href="#rid4">4,28,39,57,60,74-80</a>]. In a meta-analysis of 25 studies, sensitivity and specificity of PCR to detect invasive aspergillosis were 84 and 76 percent, respectively [<a href="#rid79">79</a>]. When at least two PCR results were positive, the sensitivity was 64 percent and the specificity was 95 percent. Another meta-analysis had similar findings [<a href="#rid80">80</a>]. These results suggest that two positive PCR results are highly suggestive of invasive aspergillosis. Standardized protocols for nucleic acid extraction, sample types, volumes, and processing have been developed by the European Aspergillus PCR Initiative/Fungal PCR Initiative [<a href="#rid3">3</a>]. </p><p class="headingAnchor" id="H20625319"><span class="h2">Assays under development</span><span class="headingEndMark"> — </span>While multiple assays are under development, recent publications have focused on two tests as aids to diagnose aspergillosis:</p><p class="bulletIndent1"><span class="glyph">●</span>A lateral flow device (LFD) that detects a mannoprotein produced by actively growing <em>Aspergillus s</em>pecies using a monoclonal JF5 antibody (<em>Asp</em>LFD) has been found to have reasonable performance in patients at risk for aspergillosis (hematologic malignancy, solid organ transplant. In a case-control study, performance of the LFD compared with galactomannan and PCR was relatively comparable when applied to serum [<a href="#rid81">81</a>]. Other studies have compared performance of the LFD with the galactomannan and beta-D-glucan assays on BAL fluid, finding promising results in patients with hematologic malignancies, solid organ transplant, or respiratory disease [<a href="#rid82">82,83</a>]. The LFD assay is inexpensive, does not require special equipment, and can be performed quickly at the point of care [<a href="#rid24">24</a>]. An updated version of that assay was shown to improve clinical utility and is marketed as a diagnostic aid [<a href="#rid84">84</a>]. Another <em>Aspergillus </em>LFD detecting galactomannan in serum is Conformitè Europëenne cleared (sona <em>Aspergillus g</em>alactomannan lateral flow assay) and shows good agreement with conventional galactomannan measurement [<a href="#rid85">85</a>]. Additionally, a lateral flow dipstick assay undergoing development which uses a galactofuranose-specific antibody successfully detected <em>Aspergillus an</em>tigens in urine in preclinical studies, which could be a rapid and easy to perform point-of-use test [<a href="#rid86">86</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another technology relies on detection of secondary metabolites in human breath using thermal desorption-gas chromatography/mass spectrometry. Results of a small prospective study that enrolled patients diagnosed with proven or probable invasive aspergillosis reported high sensitivity (94 percent; 95% CI 81-98 percent) and specificity (95% CI 79-98 percent) [<a href="#rid87">87</a>].</p><p></p><p>While these assays require more study to define performance parameters, they appear promising.</p><p class="headingAnchor" id="H20625409"><span class="h2">Combining assays</span><span class="headingEndMark"> — </span>In a meta-analysis of studies that assessed the diagnostic performance of serum galactomannan and serum or whole-blood PCR as weekly screening in high-risk patients, single positive test results had good sensitivity (92 percent for galactomannan; 84 percent for PCR) and specificity (90 percent for galactomannan; 76 percent for PCR) for detecting proven or probable invasive aspergillosis [<a href="#rid88">88</a>]. However, when positivity was defined as at least one positive result (either galactomannan or PCR), the sensitivity was 99 percent. When both the galactomannan and the PCR results were positive for the same patient, the specificity was 98 percent; specificity was also high with two positive galactomannan results (95 percent) or two positive PCR results (93 percent). In an open-label randomized trial of high-risk patients with hematologic malignancies who were not receiving antifungal prophylaxis, treating physicians were informed of either serum galactomannan and PCR results or of serum galactomannan results only; testing was performed twice weekly [<a href="#rid89">89</a>]. Positivity of either assay prompted chest computed tomography (CT) scan and initiation of antifungal therapy. The use of the serum galactomannan assay and PCR for screening was associated with earlier diagnosis and a lower incidence of invasive aspergillosis than the use of the galactomannan assay alone.</p><p>Most studies comparing the performance parameters of different assays (the galactomannan EIA, beta-D-glucan assay, LFD, and PCR) for use on BAL fluid emphasize the insensitivity of culture for isolation of <em>Aspergillus</em> species and suggest that the best approach may be to combine assays [<a href="#rid83">83</a>]. In a total of 78 BAL fluid samples, the sensitivity of all four methods ranged from 70 to 88 percent. The combination of the galactomannan EIA and either PCR or LFD increased sensitivity to 94 to 100 percent without compromising specificity. The beta-D-glucan assay applied on BAL fluid resulted in high false-positive rates.</p><p class="headingAnchor" id="H1064486487"><span class="h2">Precipitin antibodies</span><span class="headingEndMark"> — </span>Detection of precipitin antibodies may be useful for the diagnosis of allergy to various molds, including <em>Aspergillus</em>, but has no role in the diagnosis of invasive aspergillosis. (See  <a class="medical medical_review" href="/z/d/html/2419.html" rel="external">"Clinical manifestations and diagnosis of allergic bronchopulmonary aspergillosis", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H3038539"><span class="h2">Imaging</span><span class="headingEndMark"> — </span>Imaging is an important component of the diagnostic evaluation. The lungs are the most commonly affected site in invasive aspergillosis; CT scanning of the lungs often helps to support the diagnosis  (<a class="graphic graphic_diagnosticimage graphicRef56195" href="/z/d/graphic/56195.html" rel="external">image 1</a>). In patients with clinical findings suggestive of sinus involvement, CT of the sinuses should be performed  (<a class="graphic graphic_diagnosticimage graphicRef66095" href="/z/d/graphic/66095.html" rel="external">image 2</a>). When brain involvement is suspected, brain magnetic resonance imaging is indicated  (<a class="graphic graphic_diagnosticimage graphicRef71228" href="/z/d/graphic/71228.html" rel="external">image 3</a> and <a class="graphic graphic_diagnosticimage graphicRef50013" href="/z/d/graphic/50013.html" rel="external">image 4</a>).</p><p>The imaging findings associated with invasive pulmonary aspergillosis, such as nodules with surrounding hypoattenuation, termed the halo sign, can be seen with other angioinvasive pulmonary infections  (<a class="graphic graphic_diagnosticimage graphicRef56195" href="/z/d/graphic/56195.html" rel="external">image 1</a>). However, this finding most often represents invasive aspergillosis because it is the most common mold to cause invasive infection. The "reversed halo" sign has been described to be potentially a more pathognomonic pattern for mucormycosis, as the inner zone of hypoattenuation corresponds with early progression of necrosis with the agents of mucormycosis [<a href="#rid90">90</a>]. Imaging findings in patients with invasive aspergillosis are presented in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/2454.html" rel="external">"Epidemiology and clinical manifestations of invasive aspergillosis", section on 'Imaging'</a>.)</p><p class="headingAnchor" id="H1969855894"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/109727.html" rel="external">"Society guideline links: Aspergillosis"</a>.)</p><p class="headingAnchor" id="H93589236"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/83434.html" rel="external">"Patient education: Invasive aspergillosis (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H14375356"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Colonization versus invasive disease</strong> – <em>Aspergillus</em> conidia are frequently inhaled into the airways but, because of effective clearance in the majority of individuals, disease usually does not result. Because we inhale conidia constantly, culture isolation of <em>Aspergillus</em> species from the airway does not necessarily indicate disease. Thus, the diagnosis of invasive aspergillosis is based upon both isolating the organism (or markers of the organism) and the probability that it is the cause of disease. (See <a class="local">'Diagnostic modalities'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic approach</strong> – A rational first step to establishing the diagnosis of invasive aspergillosis involves the use of noninvasive modalities, such as serum biomarkers (galactomannan, beta-D-glucan assays, and polymerase chain reaction [PCR] testing) and obtaining sputum for fungal staining and culture. If the diagnosis is not made by these methods, a more invasive approach is indicated when feasible. Options include bronchoscopy with bronchoalveolar lavage (BAL), transbronchial biopsy, computed tomography–guided transthoracic needle biopsy, and video-assisted thorascopic surgery. When BAL is performed, a sample should be sent for galactomannan antigen testing. (See <a class="local">'Approach to diagnosis'</a> above.)</p><p></p><p class="bulletIndent1">Culture in combination with evidence of tissue invasion on histopathology or culture from a normally sterile site provides the most certain evidence of invasive aspergillosis. However, both microscopic examination and culture are insensitive, and therapy should not be withheld in the absence of such confirmation. (See <a class="local">'Culture'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Biopsy findings</strong> – <em>Aspergillus</em> organisms observed in biopsy specimens are typically narrow (3 to 6 microns wide), septated hyaline hyphae with acute angle branching  (<a class="graphic graphic_picture graphicRef68747" href="/z/d/graphic/68747.html" rel="external">picture 1</a> and <a class="graphic graphic_picture graphicRef57220" href="/z/d/graphic/57220.html" rel="external">picture 2</a>). However, several hyaline molds including <em>Scedosporium</em> spp and <em>Fusarium </em>spp have similar appearances to <em>Aspergillus </em>spp in histopathologic sections. The treatment of infections caused by these fungi may differ, so it is important to obtain cultures to confirm genus and species. (See <a class="local">'Histopathology'</a> above.)</p><p></p><p class="bulletIndent1">Histopathologic examination can usually distinguish <em>Aspergillus</em> spp and the other fungi described above from the Mucorales, which appear as broad, nonseptate hyphae that exhibit right angle branching  (<a class="graphic graphic_picture graphicRef66476" href="/z/d/graphic/66476.html" rel="external">picture 4</a> and <a class="graphic graphic_picture graphicRef72487" href="/z/d/graphic/72487.html" rel="external">picture 5</a>). Determining whether the fungus is a Mucorales is important because these molds are not susceptible to <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a>, which is the treatment of choice for invasive aspergillosis. (See <a class="local">'Histopathology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis when biopsy is not feasible</strong> – Performing a biopsy is not feasible in some patients due to the risk of bleeding or other complications. In patients with risk factors and clinical and/or radiographic features that are suggestive of invasive aspergillosis, culture of <em>Aspergillus</em> spp from respiratory secretions or finding typical hyphae on staining of respiratory secretions provides adequate evidence to warrant therapy. (See <a class="local">'Culture'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of biomarkers</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Galactomannan</strong> – Galactomannan is a major constituent of <em>Aspergillus</em> cell walls. A double sandwich enzyme immunoassay that detects the galactomannan antigen by binding to galactofuranose side chains is available for use on serum and BAL fluid as an adjunctive test for the diagnosis of aspergillosis. The utility of the serum galactomannan assay has been best established in the setting of suspected disease in patients with hematologic malignancies. (See <a class="local">'Galactomannan antigen detection'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Beta-D-glucan</strong> – 1,3-Beta-D-glucan, a cell wall component of many fungi, is detected by the beta-D-glucan assay. However, this assay is not specific for <em>Aspergillus</em> species and can be positive in patients with a variety of invasive fungal infections, including candidiasis and <em>Pneumocystis jirovecii </em>(formerly <em>P. carinii</em>). (See <a class="local">'Beta-D-glucan assay'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Polymerase chain reaction (PCR)</strong> – PCR for <em>Aspergillus </em>DNA can be performed on serum, plasma, whole blood, and/or BAL fluid. As with other biomarkers, a positive result can provide a presumptive diagnosis in the right clinical context; diagnostic certainty rises with two or more consecutive positive results. (See <a class="local">'Polymerase chain reaction'</a> above.)</p><p></p><p class="headingAnchor" id="H1265414129"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Kieren A Marr, MD and Daniel J Sexton, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Patterson TF, Thompson GR 3rd, Denning DW, et al. Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 63:e1.</a></li><li><a class="nounderline abstract_t">Donnelly JP, Chen SC, Kauffman CA, et al. Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis 2020; 71:1367.</a></li><li><a class="nounderline abstract_t">White PL, Bretagne S, Caliendo AM, et al. Aspergillus Polymerase Chain Reaction-An Update on Technical Recommendations, Clinical Applications, and Justification for Inclusion in the Second Revision of the EORTC/MSGERC Definitions of Invasive Fungal Disease. Clin Infect Dis 2021; 72:S95.</a></li><li><a class="nounderline abstract_t">White PL, Wingard JR, Bretagne S, et al. Aspergillus Polymerase Chain Reaction: Systematic Review of Evidence for Clinical Use in Comparison With Antigen Testing. Clin Infect Dis 2015; 61:1293.</a></li><li><a class="nounderline abstract_t">Thompson Iii GR, Cornely OA, Pappas PG, et al. Invasive Aspergillosis as an Under-recognized Superinfection in COVID-19. Open Forum Infect Dis 2020; 7:ofaa242.</a></li><li><a class="nounderline abstract_t">Janssen NAF, Nyga R, Vanderbeke L, et al. Multinational Observational Cohort Study of COVID-19-Associated Pulmonary Aspergillosis1. Emerg Infect Dis 2021; 27:2892.</a></li><li><a class="nounderline abstract_t">Koehler P, Bassetti M, Chakrabarti A, et al. Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. Lancet Infect Dis 2021; 21:e149.</a></li><li><a class="nounderline abstract_t">Verweij PE, Brüggemann RJM, Azoulay E, et al. Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis. Intensive Care Med 2021; 47:819.</a></li><li><a class="nounderline abstract_t">Fortarezza F, Boscolo A, Pezzuto F, et al. Proven COVID-19-associated pulmonary aspergillosis in patients with severe respiratory failure. Mycoses 2021; 64:1223.</a></li><li><a class="nounderline abstract_t">De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46:1813.</a></li><li><a class="nounderline abstract_t">Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34:7.</a></li><li class="breakAll">Procop GW, Hayden RT, Roberts GD. Filamentous fungi. In: Diagnostic Microbiology of the Immunocompromised Host, Hayden RT, Carroll KC, Tang YW, Wolk DM (Eds), ASM Press, Washington DC 2009. p.195.</li><li class="breakAll">Verweij PE, Brandt ME. Aspergillus, Fusarium, and Other Opportunistic Moniliaceous Fungi. In: Manual of Clinical Microbiology, 9th Ed, Murray PR, Baron EJ, Landry ML, Jorgenesen JH, et al (Eds), ASM Press, Washington DC 2007. Vol 2, p.1802.</li><li><a class="nounderline abstract_t">Cuenca-Estrella M, Bassetti M, Lass-Flörl C, et al. Detection and investigation of invasive mould disease. J Antimicrob Chemother 2011; 66 Suppl 1:i15.</a></li><li><a class="nounderline abstract_t">Balajee SA, Kano R, Baddley JW, et al. Molecular identification of Aspergillus species collected for the Transplant-Associated Infection Surveillance Network. J Clin Microbiol 2009; 47:3138.</a></li><li><a class="nounderline abstract_t">Neofytos D, Horn D, Anaissie E, et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis 2009; 48:265.</a></li><li><a class="nounderline abstract_t">Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 2010; 50:1091.</a></li><li><a class="nounderline abstract_t">Horvath JA, Dummer S. The use of respiratory-tract cultures in the diagnosis of invasive pulmonary aspergillosis. Am J Med 1996; 100:171.</a></li><li><a class="nounderline abstract_t">Kudoh A, Okawa Y, Shibata N. Significant structural change in both O- and N-linked carbohydrate moieties of the antigenic galactomannan from Aspergillus fumigatus grown under different culture conditions. Glycobiology 2015; 25:74.</a></li><li><a class="nounderline abstract_t">Tefsen B, Ram AF, van Die I, Routier FH. Galactofuranose in eukaryotes: aspects of biosynthesis and functional impact. Glycobiology 2012; 22:456.</a></li><li><a class="nounderline abstract_t">Maertens J, Theunissen K, Verbeken E, et al. Prospective clinical evaluation of lower cut-offs for galactomannan detection in adult neutropenic cancer patients and haematological stem cell transplant recipients. Br J Haematol 2004; 126:852.</a></li><li><a class="nounderline abstract_t">Marr KA, Balajee SA, McLaughlin L, et al. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J Infect Dis 2004; 190:641.</a></li><li><a class="nounderline abstract_t">Mercier T, Castagnola E, Marr KA, et al. Defining Galactomannan Positivity in the Updated EORTC/MSGERC Consensus Definitions of Invasive Fungal Diseases. Clin Infect Dis 2021; 72:S89.</a></li><li><a class="nounderline abstract_t">Miceli MH, Maertens J. Role of Non-Culture-Based Tests, with an Emphasis on Galactomannan Testing for the Diagnosis of Invasive Aspergillosis. Semin Respir Crit Care Med 2015; 36:650.</a></li><li><a class="nounderline abstract_t">Leeflang MM, Debets-Ossenkopp YJ, Wang J, et al. Galactomannan detection for invasive aspergillosis in immunocompromised patients. Cochrane Database Syst Rev 2015; :CD007394.</a></li><li><a class="nounderline abstract_t">Marr KA, Leisenring W. Design issues in studies evaluating diagnostic tests for aspergillosis. Clin Infect Dis 2005; 41 Suppl 6:S381.</a></li><li><a class="nounderline abstract_t">Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis 2006; 42:1417.</a></li><li><a class="nounderline abstract_t">Marr KA, Laverdiere M, Gugel A, Leisenring W. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis 2005; 40:1762.</a></li><li><a class="nounderline abstract_t">Duarte RF, Sánchez-Ortega I, Cuesta I, et al. Serum galactomannan-based early detection of invasive aspergillosis in hematology patients receiving effective antimold prophylaxis. Clin Infect Dis 2014; 59:1696.</a></li><li><a class="nounderline abstract_t">Cornely OA. Galactomannan testing during mold-active prophylaxis. Clin Infect Dis 2014; 59:1703.</a></li><li><a class="nounderline abstract_t">Mennink-Kersten MA, Donnelly JP, Verweij PE. Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. Lancet Infect Dis 2004; 4:349.</a></li><li><a class="nounderline abstract_t">Walsh TJ, Shoham S, Petraitiene R, et al. Detection of galactomannan antigenemia in patients receiving piperacillin-tazobactam and correlations between in vitro, in vivo, and clinical properties of the drug-antigen interaction. J Clin Microbiol 2004; 42:4744.</a></li><li><a class="nounderline abstract_t">Aubry A, Porcher R, Bottero J, et al. Occurrence and kinetics of false-positive Aspergillus galactomannan test results following treatment with beta-lactam antibiotics in patients with hematological disorders. J Clin Microbiol 2006; 44:389.</a></li><li><a class="nounderline abstract_t">Mikulska M, Furfaro E, Del Bono V, et al. Piperacillin/tazobactam (Tazocin™) seems to be no longer responsible for false-positive results of the galactomannan assay. J Antimicrob Chemother 2012; 67:1746.</a></li><li><a class="nounderline abstract_t">Vergidis P, Razonable RR, Wheat LJ, et al. Reduction in false-positive Aspergillus serum galactomannan enzyme immunoassay results associated with use of piperacillin-tazobactam in the United States. J Clin Microbiol 2014; 52:2199.</a></li><li><a class="nounderline abstract_t">Mattei D, Rapezzi D, Mordini N, et al. False-positive Aspergillus galactomannan enzyme-linked immunosorbent assay results in vivo during amoxicillin-clavulanic acid treatment. J Clin Microbiol 2004; 42:5362.</a></li><li><a class="nounderline abstract_t">Tortorano AM, Esposto MC, Prigitano A, et al. Cross-reactivity of Fusarium spp. in the Aspergillus Galactomannan enzyme-linked immunosorbent assay. J Clin Microbiol 2012; 50:1051.</a></li><li><a class="nounderline abstract_t">Huang YT, Hung CC, Hsueh PR. Aspergillus galactomannan antigenemia in penicilliosis marneffei. AIDS 2007; 21:1990.</a></li><li><a class="nounderline abstract_t">Wheat LJ, Hackett E, Durkin M, et al. Histoplasmosis-associated cross-reactivity in the BioRad Platelia Aspergillus enzyme immunoassay. Clin Vaccine Immunol 2007; 14:638.</a></li><li><a class="nounderline abstract_t">Asano-Mori Y, Kanda Y, Oshima K, et al. False-positive Aspergillus galactomannan antigenaemia after haematopoietic stem cell transplantation. J Antimicrob Chemother 2008; 61:411.</a></li><li><a class="nounderline abstract_t">Guigue N, Menotti J, Ribaud P. False positive galactomannan test after ice-pop ingestion. N Engl J Med 2013; 369:97.</a></li><li><a class="nounderline abstract_t">Martín-Rabadán P, Gijón P, Alonso Fernández R, et al. False-positive Aspergillus antigenemia due to blood product conditioning fluids. Clin Infect Dis 2012; 55:e22.</a></li><li><a class="nounderline abstract_t">Ramsay I, Gorton RL, Patel M, et al. Transmission of Hepatitis B Core Antibody and Galactomannan Enzyme Immunoassay Positivity via Immunoglobulin Products: A Comprehensive Analysis. Clin Infect Dis 2016; 63:57.</a></li><li><a class="nounderline abstract_t">Steinbach WJ, Addison RM, McLaughlin L, et al. Prospective Aspergillus galactomannan antigen testing in pediatric hematopoietic stem cell transplant recipients. Pediatr Infect Dis J 2007; 26:558.</a></li><li><a class="nounderline abstract_t">Morrissey CO, Chen SC, Sorrell TC, et al. Galactomannan and PCR versus culture and histology for directing use of antifungal treatment for invasive aspergillosis in high-risk haematology patients: a randomised controlled trial. Lancet Infect Dis 2013; 13:519.</a></li><li><a class="nounderline abstract_t">Miceli MH, Grazziutti ML, Woods G, et al. Strong correlation between serum aspergillus galactomannan index and outcome of aspergillosis in patients with hematological cancer: clinical and research implications. Clin Infect Dis 2008; 46:1412.</a></li><li><a class="nounderline abstract_t">Miceli MH, Maertens J, Buvé K, et al. Immune reconstitution inflammatory syndrome in cancer patients with pulmonary aspergillosis recovering from neutropenia: Proof of principle, description, and clinical and research implications. Cancer 2007; 110:112.</a></li><li><a class="nounderline abstract_t">Woods G, Miceli MH, Grazziutti ML, et al. Serum Aspergillus galactomannan antigen values strongly correlate with outcome of invasive aspergillosis: a study of 56 patients with hematologic cancer. Cancer 2007; 110:830.</a></li><li><a class="nounderline abstract_t">Koo S, Bryar JM, Baden LR, Marty FM. Prognostic features of galactomannan antigenemia in galactomannan-positive invasive aspergillosis. J Clin Microbiol 2010; 48:1255.</a></li><li><a class="nounderline abstract_t">Nouér SA, Nucci M, Kumar NS, et al. Earlier response assessment in invasive aspergillosis based on the kinetics of serum Aspergillus galactomannan: proposal for a new definition. Clin Infect Dis 2011; 53:671.</a></li><li><a class="nounderline abstract_t">Husain S, Clancy CJ, Nguyen MH, et al. Performance characteristics of the platelia Aspergillus enzyme immunoassay for detection of Aspergillus galactomannan antigen in bronchoalveolar lavage fluid. Clin Vaccine Immunol 2008; 15:1760.</a></li><li><a class="nounderline abstract_t">Musher B, Fredricks D, Leisenring W, et al. Aspergillus galactomannan enzyme immunoassay and quantitative PCR for diagnosis of invasive aspergillosis with bronchoalveolar lavage fluid. J Clin Microbiol 2004; 42:5517.</a></li><li><a class="nounderline abstract_t">Maertens J, Maertens V, Theunissen K, et al. Bronchoalveolar lavage fluid galactomannan for the diagnosis of invasive pulmonary aspergillosis in patients with hematologic diseases. Clin Infect Dis 2009; 49:1688.</a></li><li><a class="nounderline abstract_t">D'Haese J, Theunissen K, Vermeulen E, et al. Detection of galactomannan in bronchoalveolar lavage fluid samples of patients at risk for invasive pulmonary aspergillosis: analytical and clinical validity. J Clin Microbiol 2012; 50:1258.</a></li><li><a class="nounderline abstract_t">de Heer K, Gerritsen MG, Visser CE, Leeflang MM. Galactomannan detection in broncho-alveolar lavage fluid for invasive aspergillosis in immunocompromised patients. Cochrane Database Syst Rev 2019; 5:CD012399.</a></li><li><a class="nounderline abstract_t">Klont RR, Mennink-Kersten MA, Verweij PE. Utility of Aspergillus antigen detection in specimens other than serum specimens. Clin Infect Dis 2004; 39:1467.</a></li><li><a class="nounderline abstract_t">Pickering JW, Sant HW, Bowles CA, et al. Evaluation of a (1-&gt;3)-beta-D-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol 2005; 43:5957.</a></li><li><a class="nounderline abstract_t">Karageorgopoulos DE, Vouloumanou EK, Ntziora F, et al. β-D-glucan assay for the diagnosis of invasive fungal infections: a meta-analysis. Clin Infect Dis 2011; 52:750.</a></li><li><a class="nounderline abstract_t">Lamoth F, Cruciani M, Mengoli C, et al. β-Glucan antigenemia assay for the diagnosis of invasive fungal infections in patients with hematological malignancies: a systematic review and meta-analysis of cohort studies from the Third European Conference on Infections in Leukemia (ECIL-3). Clin Infect Dis 2012; 54:633.</a></li><li><a class="nounderline abstract_t">Kawazu M, Kanda Y, Nannya Y, et al. Prospective comparison of the diagnostic potential of real-time PCR, double-sandwich enzyme-linked immunosorbent assay for galactomannan, and a (1--&gt;3)-beta-D-glucan test in weekly screening for invasive aspergillosis in patients with hematological disorders. J Clin Microbiol 2004; 42:2733.</a></li><li><a class="nounderline abstract_t">Obayashi T, Negishi K, Suzuki T, Funata N. Reappraisal of the serum (1--&gt;3)-beta-D-glucan assay for the diagnosis of invasive fungal infections--a study based on autopsy cases from 6 years. Clin Infect Dis 2008; 46:1864.</a></li><li><a class="nounderline abstract_t">Odabasi Z, Mattiuzzi G, Estey E, et al. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 2004; 39:199.</a></li><li><a class="nounderline abstract_t">Ostrosky-Zeichner L, Alexander BD, Kett DH, et al. Multicenter clinical evaluation of the (1--&gt;3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005; 41:654.</a></li><li><a class="nounderline abstract_t">Koo S, Bryar JM, Page JH, et al. Diagnostic performance of the (1--&gt;3)-beta-D-glucan assay for invasive fungal disease. Clin Infect Dis 2009; 49:1650.</a></li><li><a class="nounderline abstract_t">Sulahian A, Porcher R, Bergeron A, et al. Use and limits of (1-3)-β-d-glucan assay (Fungitell), compared to galactomannan determination (Platelia Aspergillus), for diagnosis of invasive aspergillosis. J Clin Microbiol 2014; 52:2328.</a></li><li><a class="nounderline abstract_t">Marty FM, Koo S. Role of (1--&gt;3)-beta-D-glucan in the diagnosis of invasive aspergillosis. Med Mycol 2009; 47 Suppl 1:S233.</a></li><li><a class="nounderline abstract_t">Obayashi T, Yoshida M, Mori T, et al. Plasma (1--&gt;3)-beta-D-glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes. Lancet 1995; 345:17.</a></li><li><a class="nounderline abstract_t">Szyszkowitz A, Zurl C, Herzeg A, et al. Serum 1,3-Beta-D-Glucan Values During and After Laparoscopic and Open Intestinal Surgery. Open Forum Infect Dis 2018; 5:ofy296.</a></li><li><a class="nounderline abstract_t">Mennink-Kersten MA, Warris A, Verweij PE. 1,3-beta-D-glucan in patients receiving intravenous amoxicillin-clavulanic acid. N Engl J Med 2006; 354:2834.</a></li><li><a class="nounderline abstract_t">Mennink-Kersten MA, Ruegebrink D, Verweij PE. Pseudomonas aeruginosa as a cause of 1,3-beta-D-glucan assay reactivity. Clin Infect Dis 2008; 46:1930.</a></li><li><a class="nounderline abstract_t">Mennink-Kersten MA, Verweij PE. Non-culture-based diagnostics for opportunistic fungi. Infect Dis Clin North Am 2006; 20:711.</a></li><li><a class="nounderline abstract_t">Pazos C, Pontón J, Del Palacio A. Contribution of (1-&gt;3)-beta-D-glucan chromogenic assay to diagnosis and therapeutic monitoring of invasive aspergillosis in neutropenic adult patients: a comparison with serial screening for circulating galactomannan. J Clin Microbiol 2005; 43:299.</a></li><li><a class="nounderline abstract_t">Lamoth F, Akan H, Andes D, et al. Assessment of the Role of 1,3-β-d-Glucan Testing for the Diagnosis of Invasive Fungal Infections in Adults. Clin Infect Dis 2021; 72:S102.</a></li><li><a class="nounderline abstract_t">Costa C, Costa JM, Desterke C, et al. Real-time PCR coupled with automated DNA extraction and detection of galactomannan antigen in serum by enzyme-linked immunosorbent assay for diagnosis of invasive aspergillosis. J Clin Microbiol 2002; 40:2224.</a></li><li><a class="nounderline abstract_t">Donnelly JP. Polymerase chain reaction for diagnosing invasive aspergillosis: getting closer but still a ways to go. Clin Infect Dis 2006; 42:487.</a></li><li><a class="nounderline abstract_t">Loeffler J, Kloepfer K, Hebart H, et al. Polymerase chain reaction detection of aspergillus DNA in experimental models of invasive aspergillosis. J Infect Dis 2002; 185:1203.</a></li><li><a class="nounderline abstract_t">Raad I, Hanna H, Sumoza D, Albitar M. Polymerase chain reaction on blood for the diagnosis of invasive pulmonary aspergillosis in cancer patients. Cancer 2002; 94:1032.</a></li><li><a class="nounderline abstract_t">Singh N, Arnow PM, Bonham A, et al. Invasive aspergillosis in liver transplant recipients in the 1990s. Transplantation 1997; 64:716.</a></li><li><a class="nounderline abstract_t">Arvanitis M, Ziakas PD, Zacharioudakis IM, et al. PCR in diagnosis of invasive aspergillosis: a meta-analysis of diagnostic performance. J Clin Microbiol 2014; 52:3731.</a></li><li><a class="nounderline abstract_t">Cruciani M, Mengoli C, Loeffler J, et al. Polymerase chain reaction blood tests for the diagnosis of invasive aspergillosis in immunocompromised people. Cochrane Database Syst Rev 2015; :CD009551.</a></li><li><a class="nounderline abstract_t">White PL, Parr C, Thornton C, Barnes RA. Evaluation of real-time PCR, galactomannan enzyme-linked immunosorbent assay (ELISA), and a novel lateral-flow device for diagnosis of invasive aspergillosis. J Clin Microbiol 2013; 51:1510.</a></li><li><a class="nounderline abstract_t">Prattes J, Flick H, Prüller F, et al. Novel tests for diagnosis of invasive aspergillosis in patients with underlying respiratory diseases. Am J Respir Crit Care Med 2014; 190:922.</a></li><li><a class="nounderline abstract_t">Hoenigl M, Prattes J, Spiess B, et al. Performance of galactomannan, beta-d-glucan, Aspergillus lateral-flow device, conventional culture, and PCR tests with bronchoalveolar lavage fluid for diagnosis of invasive pulmonary aspergillosis. J Clin Microbiol 2014; 52:2039.</a></li><li><a class="nounderline abstract_t">Hoenigl M, Eigl S, Heldt S, et al. Clinical evaluation of the newly formatted lateral-flow device for invasive pulmonary aspergillosis. Mycoses 2018; 61:40.</a></li><li><a class="nounderline abstract_t">Hoenigl M, Egger M, Boyer J, et al. Serum Lateral Flow assay with digital reader for the diagnosis of invasive pulmonary aspergillosis: A two-centre mixed cohort study. Mycoses 2021; 64:1197.</a></li><li><a class="nounderline abstract_t">Marr KA, Datta K, Mehta S, et al. Urine Antigen Detection as an Aid to Diagnose Invasive Aspergillosis. Clin Infect Dis 2018; 67:1705.</a></li><li><a class="nounderline abstract_t">Koo S, Thomas HR, Daniels SD, et al. A breath fungal secondary metabolite signature to diagnose invasive aspergillosis. Clin Infect Dis 2014; 59:1733.</a></li><li><a class="nounderline abstract_t">Arvanitis M, Anagnostou T, Mylonakis E. Galactomannan and Polymerase Chain Reaction-Based Screening for Invasive Aspergillosis Among High-Risk Hematology Patients: A Diagnostic Meta-analysis. Clin Infect Dis 2015; 61:1263.</a></li><li><a class="nounderline abstract_t">Aguado JM, Vázquez L, Fernández-Ruiz M, et al. Serum galactomannan versus a combination of galactomannan and polymerase chain reaction-based Aspergillus DNA detection for early therapy of invasive aspergillosis in high-risk hematological patients: a randomized controlled trial. Clin Infect Dis 2015; 60:405.</a></li><li><a class="nounderline abstract_t">Legouge C, Caillot D, Chrétien ML, et al. The reversed halo sign: pathognomonic pattern of pulmonary mucormycosis in leukemic patients with neutropenia? Clin Infect Dis 2014; 58:672.</a></li></ol></div><div id="topicVersionRevision">Topic 15717 Version 46.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27365388" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31802125" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33709129" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Aspergillus Polymerase Chain Reaction-An Update on Technical Recommendations, Clinical Applications, and Justification for Inclusion in the Second Revision of the EORTC/MSGERC Definitions of Invasive Fungal Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26113653" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Aspergillus Polymerase Chain Reaction: Systematic Review of Evidence for Clinical Use in Comparison With Antigen Testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32754626" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Invasive Aspergillosis as an Under-recognized Superinfection in COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34519638" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Multinational Observational Cohort Study of COVID-19-Associated Pulmonary Aspergillosis1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33333012" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34160631" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34157166" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Proven COVID-19-associated pulmonary aspergillosis in patients with severe respiratory failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18462102" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11731939" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11731939" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11731939" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21177400" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Detection and investigation of invasive mould disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19675215" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Molecular identification of Aspergillus species collected for the Transplant-Associated Infection Surveillance Network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19115967" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20218877" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8629651" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The use of respiratory-tract cultures in the diagnosis of invasive pulmonary aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25187160" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Significant structural change in both O- and N-linked carbohydrate moieties of the antigenic galactomannan from Aspergillus fumigatus grown under different culture conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21940757" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Galactofuranose in eukaryotes: aspects of biosynthesis and functional impact.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15352990" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Prospective clinical evaluation of lower cut-offs for galactomannan detection in adult neutropenic cancer patients and haematological stem cell transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15243943" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33709125" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Defining Galactomannan Positivity in the Updated EORTC/MSGERC Consensus Definitions of Invasive Fungal Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26398532" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Role of Non-Culture-Based Tests, with an Emphasis on Galactomannan Testing for the Diagnosis of Invasive Aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26716951" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Galactomannan detection for invasive aspergillosis in immunocompromised patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16108003" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Design issues in studies evaluating diagnostic tests for aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16619154" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15909264" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25165088" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Serum galactomannan-based early detection of invasive aspergillosis in hematology patients receiving effective antimold prophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25165089" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Galactomannan testing during mold-active prophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15172343" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15472335" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Detection of galactomannan antigenemia in patients receiving piperacillin-tazobactam and correlations between in vitro, in vivo, and clinical properties of the drug-antigen interaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16455889" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Occurrence and kinetics of false-positive Aspergillus galactomannan test results following treatment with beta-lactam antibiotics in patients with hematological disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22499998" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Piperacillin/tazobactam (Tazocin™) seems to be no longer responsible for false-positive results of the galactomannan assay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24719434" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Reduction in false-positive Aspergillus serum galactomannan enzyme immunoassay results associated with use of piperacillin-tazobactam in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15528743" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : False-positive Aspergillus galactomannan enzyme-linked immunosorbent assay results in vivo during amoxicillin-clavulanic acid treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22205818" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Cross-reactivity of Fusarium spp. in the Aspergillus Galactomannan enzyme-linked immunosorbent assay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17721116" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Aspergillus galactomannan antigenemia in penicilliosis marneffei.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17344352" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Histoplasmosis-associated cross-reactivity in the BioRad Platelia Aspergillus enzyme immunoassay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18055488" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : False-positive Aspergillus galactomannan antigenaemia after haematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23822795" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : False positive galactomannan test after ice-pop ingestion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22610929" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : False-positive Aspergillus antigenemia due to blood product conditioning fluids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27076567" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Transmission of Hepatitis B Core Antibody and Galactomannan Enzyme Immunoassay Positivity via Immunoglobulin Products: A Comprehensive Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17596794" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Prospective Aspergillus galactomannan antigen testing in pediatric hematopoietic stem cell transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23639612" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Galactomannan and PCR versus culture and histology for directing use of antifungal treatment for invasive aspergillosis in high-risk haematology patients: a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18419445" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Strong correlation between serum aspergillus galactomannan index and outcome of aspergillosis in patients with hematological cancer: clinical and research implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17525971" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Immune reconstitution inflammatory syndrome in cancer patients with pulmonary aspergillosis recovering from neutropenia: Proof of principle, description, and clinical and research implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17607669" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Serum Aspergillus galactomannan antigen values strongly correlate with outcome of invasive aspergillosis: a study of 56 patients with hematologic cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20147646" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Prognostic features of galactomannan antigenemia in galactomannan-positive invasive aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21846834" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Earlier response assessment in invasive aspergillosis based on the kinetics of serum Aspergillus galactomannan: proposal for a new definition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18845830" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Performance characteristics of the platelia Aspergillus enzyme immunoassay for detection of Aspergillus galactomannan antigen in bronchoalveolar lavage fluid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15583275" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Aspergillus galactomannan enzyme immunoassay and quantitative PCR for diagnosis of invasive aspergillosis with bronchoalveolar lavage fluid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19886801" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Bronchoalveolar lavage fluid galactomannan for the diagnosis of invasive pulmonary aspergillosis in patients with hematologic diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22301025" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Detection of galactomannan in bronchoalveolar lavage fluid samples of patients at risk for invasive pulmonary aspergillosis: analytical and clinical validity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31107543" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Galactomannan detection in broncho-alveolar lavage fluid for invasive aspergillosis in immunocompromised patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15546083" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Utility of Aspergillus antigen detection in specimens other than serum specimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16333082" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Evaluation of a (1-&gt;3)-beta-D-glucan assay for diagnosis of invasive fungal infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21367728" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : β-D-glucan assay for the diagnosis of invasive fungal infections: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22198786" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : β-Glucan antigenemia assay for the diagnosis of invasive fungal infections in patients with hematological malignancies: a systematic review and meta-analysis of cohort studies from the Third European Conference on Infections in Leukemia (ECIL-3).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15184460" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Prospective comparison of the diagnostic potential of real-time PCR, double-sandwich enzyme-linked immunosorbent assay for galactomannan, and a (1--&gt;3)-beta-D-glucan test in weekly screening for invasive aspergillosis in patients with hematological disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18462174" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Reappraisal of the serum (1--&gt;3)-beta-D-glucan assay for the diagnosis of invasive fungal infections--a study based on autopsy cases from 6 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15307029" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16080087" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Multicenter clinical evaluation of the (1--&gt;3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19863452" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Diagnostic performance of the (1--&gt;3)-beta-D-glucan assay for invasive fungal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24740084" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Use and limits of (1-3)-β-d-glucan assay (Fungitell), compared to galactomannan determination (Platelia Aspergillus), for diagnosis of invasive aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18720216" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Role of (1--&gt;3)-beta-D-glucan in the diagnosis of invasive aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7799700" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Plasma (1--&gt;3)-beta-D-glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30568978" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Serum 1,3-Beta-D-Glucan Values During and After Laparoscopic and Open Intestinal Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16807428" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : 1,3-beta-D-glucan in patients receiving intravenous amoxicillin-clavulanic acid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18540808" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Pseudomonas aeruginosa as a cause of 1,3-beta-D-glucan assay reactivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16984877" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Non-culture-based diagnostics for opportunistic fungi.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15634986" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Contribution of (1-&gt;3)-beta-D-glucan chromogenic assay to diagnosis and therapeutic monitoring of invasive aspergillosis in neutropenic adult patients: a comparison with serial screening for circulating galactomannan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33709130" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Assessment of the Role of 1,3-β-d-Glucan Testing for the Diagnosis of Invasive Fungal Infections in Adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12037092" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Real-time PCR coupled with automated DNA extraction and detection of galactomannan antigen in serum by enzyme-linked immunosorbent assay for diagnosis of invasive aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16421792" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Polymerase chain reaction for diagnosing invasive aspergillosis: getting closer but still a ways to go.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11930335" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Polymerase chain reaction detection of aspergillus DNA in experimental models of invasive aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11920473" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Polymerase chain reaction on blood for the diagnosis of invasive pulmonary aspergillosis in cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9311708" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Invasive aspergillosis in liver transplant recipients in the 1990s.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25122854" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : PCR in diagnosis of invasive aspergillosis: a meta-analysis of diagnostic performance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26424726" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Polymerase chain reaction blood tests for the diagnosis of invasive aspergillosis in immunocompromised people.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23486712" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Evaluation of real-time PCR, galactomannan enzyme-linked immunosorbent assay (ELISA), and a novel lateral-flow device for diagnosis of invasive aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25203869" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Novel tests for diagnosis of invasive aspergillosis in patients with underlying respiratory diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24671798" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Performance of galactomannan, beta-d-glucan, Aspergillus lateral-flow device, conventional culture, and PCR tests with bronchoalveolar lavage fluid for diagnosis of invasive pulmonary aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28922489" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Clinical evaluation of the newly formatted lateral-flow device for invasive pulmonary aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34252244" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Serum Lateral Flow assay with digital reader for the diagnosis of invasive pulmonary aspergillosis: A two-centre mixed cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29684106" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Urine Antigen Detection as an Aid to Diagnose Invasive Aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25342502" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : A breath fungal secondary metabolite signature to diagnose invasive aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26157047" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Galactomannan and Polymerase Chain Reaction-Based Screening for Invasive Aspergillosis Among High-Risk Hematology Patients: A Diagnostic Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25336623" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Serum galactomannan versus a combination of galactomannan and polymerase chain reaction-based Aspergillus DNA detection for early therapy of invasive aspergillosis in high-risk hematological patients: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24352351" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : The reversed halo sign: pathognomonic pattern of pulmonary mucormycosis in leukemic patients with neutropenia?</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
